Ratings Hanwha Corporation

Equities

A000880

KR7000880005

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
27,350 ^KRW	-1.62%		+2.43%	+6.21%

Apr. 24	US solar panel makers seek new tariffs to protect domestic factories	RE
Apr. 17	US plans to restore tariffs on dominant solar technology, sources say	RE

Strengths

Its low valuation, with P/E ratio at 3.45 and 2.71 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 36.39 for the 2024 fiscal year.
The company's share price in relation to its net book value makes it look relatively cheap.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Life & Health Insurance

	1st Jan change	Capi.	ESG Refinitiv
HANWHA CORPORATION	+6.21%	1.5B	B
AXA	+10.00%	80.6B	B-
METLIFE, INC.	+7.49%	51.13B	B+
AFLAC INCORPORATED	+1.39%	48.65B	B
MANULIFE FINANCIAL CORPORATION	+9.67%	42.58B	B+
PRUDENTIAL FINANCIAL, INC.	+6.53%	40.23B	B+
GENERALI	+19.86%	38.14B	B
SUN LIFE FINANCIAL INC.	+2.28%	30.09B	B
GREAT-WEST LIFECO INC.	-7.16%	27.79B	B-
PRUDENTIAL PLC	-20.99%	25.5B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes